HUTCHMED (China) Limited (AIM:HCM)
United Kingdom · Delayed Price · Currency is GBP · Price in GBX | Market Cap | 1.91B -2.6% |
| Revenue (ttm) | 413.87M -8.8% |
| Net Income | 13.48M -96.2% |
| EPS | 0.02 -96.2% |
| Shares Out | 869.07M |
| PE Ratio | 144.58 |
| Forward PE | 45.10 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 16,610 |
| Open | 202.00 |
| Previous Close | 210.00 |
| Day's Range | 202.00 - 222.68 |
| 52-Week Range | 150.50 - 239.00 |
| Beta | 0.49 |
| Analysts | Buy |
| Price Target | 362.70 (+64.86%) |
| Est. Earnings | Nov 13, 2026 |
About HUTCHMED (China)
HUTCHMED (China) Limited, together with its subsidiaries, discovers, develops, and commercializes targeted therapeutics and immunotherapies to treat cancer and immunological diseases in Hong Kong, the United States, and internationally. It provides Fruquintinib, a selective and potent oral inhibitor of vascular endothelial growth factor receptors for treatment of colorectal cancer (CRC), breast cancer, gastric cancer (GC), microsatellite stable-CRC endometrial cancer (EMC), non-small cell lung cancer (NSCLC), renal cell carcinoma (RCC), endomet... [Read more]
Financial Performance
In 2025, HUTCHMED (China)'s revenue was $548.51 million, a decrease of -12.96% compared to the previous year's $630.20 million. Earnings were $456.91 million, an increase of 1111.03%.
Financial numbers in USD Financial StatementsAnalyst Summary
According to 6 analysts, the average rating for HCM stock is "Buy." The 12-month stock price target is 363p, which is an increase of 64.86% from the latest price.
News
HUTCHMED (China) Transcript: Fireside chat
SANOVO and SAFFRON reported PFS and OS benefits for savolitinib plus osimertinib in biomarker-selected NSCLC. Speakers highlighted IHC testing, oral convenience, upcoming filings and possible expansion into other tumors.
HUTCHMED's Sovleplenib Gets FDA Orphan Drug Status For Autoimmune Hemolytic Anemia
(RTTNews) - HUTCHMED (China) Ltd. (HCM) said Wednesday the U.S. Food and Drug Administration granted Orphan drug designation to Sovleplenib for autoimmune hemolytic anemia.
Hutchmed says sovleplenib granted FDA orphan drug designation
Hutchmed (HCM) announced hat the US Food and Drug Administration has granted Orphan Drug Designation to sovleplenib for the treatment of autoimmune hemolytic anemia. Sovleplenib is a novel, selective,...
HUTCHMED Announces Sovleplenib Granted US FDA Orphan Drug Designation for Autoimmune Hemolytic Anemia
— Eligible for development incentives including 7 years of US market exclusivity upon regulatory approval —
HUTCHMED Advances ORPATHYS-TAGRISSO Through EU, Japan Reviews
(RTTNews) - HUTCHMED (China) Ltd. (HCM) announced that regulatory filings for ORPATHYS (savolitinib) in combination with TAGRISSO (osimertinib) have been accepted for review in Europe and Japan.
Hutchmed announces filings for Orpathys accepted for review in Japan, Europe
Hutchmed (HCM) announces that regulatory filings for Orpathys in combination with Tagrisso have been accepted for review in Europe and Japan. In Europe, the European Medicines Agency, EMA, has validat...
HUTCHMED Announces Regulatory Filings Accepted for Review for ORPATHYS® plus TAGRISSO® in MET-Driven EGFR-Mutated Lung Cancer in Europe and Japan
— Follows US FDA new drug application submission in September 2026, marking important global regulatory progress —
HUTCHMED (China) Limited Announces Sovleplenib Granted US FDA Orphan Drug Designation for Primary Immune Thrombocytopenia
HUTCHMED (China) Limited announced that the US Food and Drug Administration has granted Orphan Drug Designation to sovleplenib for the treatment of primary immune thrombocytopenia, an autoimmune disor...
HUTCHMED Announces Sovleplenib Granted US FDA Orphan Drug Designation for Primary Immune Thrombocytopenia
— Orphan Drug Designation granted for the treatment of primary immune thrombocytopenia — — Underscores the potential of sovleplenib to address significant unmet medical needs in patients with this ra...
HUTCHMED (China) Limited to Host Expert Webcast on Savolitinib Phase III Clinical Data
HUTCHMED (China) Limited announced that it will co-host an expert webcast with Citigroup Global Markets Asia Limited for analysts and investors on Thursday, November 5, 2026, at 4:30 pm HKT / 8:30 am ...
Save the Date: HUTCHMED to Host Expert Insights Event on Recent Savolitinib Clinical Data in Non-Small Cell Lung Cancer
HONG KONG and SHANGHAI and FLORHAM PARK, N.J., Oct. 26, 2026 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:HCM; HKEX:13) today announces an expert webcast, co-hosted with Cit...
HUTCHMED Announces Positive Phase III Data for ORPATHYS plus TAGRISSO in SAFFRON and SANOVO Lung Cancer Trials
HUTCHMED (China) Limited announced positive results from the SAFFRON global Phase III trial. The combination of ORPATHYS plus TAGRISSO demonstrated a statistically significant and clinically meaningfu...
AstraZeneca's Tagrisso Combo Achieves Significant Survival Benefit In Lung Cancer Trial; Stock Up
(RTTNews) - AstraZeneca (AZN) and HUTCHMED reported Phase 3 results showing that Tagrisso (osimertinib) combined with Orpathys (savolitinib) significantly improved progression-free and overall surviva...
Hutchmed announces SANOVO trial meets primary endpoint
Hutchmed (HCM) announced results from the SANOVO Phase III trial in China. Orpathys plus Tagrisso demonstrated a statistically significant and highly clinically meaningful improvement in the primary e...
HUTCHMED Highlights SANOVO Phase III Data for ORPATHYS® plus TAGRISSO® in First-Line EGFR-Mutated Lung Cancer Presented at ESMO Congress 2026
— ORPATHYS ® plus TAGRISSO ® reduced the risk of disease progression or death by 44% in the overall population and 55% in the high MET overexpression population in the first-line setting —
HUTCHMED Highlights SAFFRON Global Phase III Data Presented at ESMO Congress 2026 and Simultaneously Published in The New England Journal of Medicine
— ORPATHYS ® plus TAGRISSO ® reduced the risk of disease progression or death by 45% and the risk of death by 32% in MET-driven EGFR-mutated lung cancer after progression on TAGRISSO ® —
HUTCHMED Announces Closing of KRAS-EGFR-Antibody Conjugate Therapy License to GSK Outside China
HONG KONG, SHANGHAI and FLORHAM PARK, N.J., Oct. 20, 2026 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED” or the “Company”) (Nasdaq/AIM:HCM; HKEX:13) today announces that further to its annou...
HUTCHMED Seeks FDA Approval For ORPATHYS-TAGRISSO In Resistant Lung Cancer
(RTTNews) - HUTCHMED (HCM) announced that AstraZeneca (AZN) has submitted a New Drug Application to the U.S. FDA for ORPATHYS in combination with TAGRISSO for certain patients with advanced non-small ...
AstraZeneca files US FDA application for HUTCHMED lung cancer drug combination
HUTCHMED (China) said on Tuesday Anglo-Swedish drugmaker AstraZeneca had filed an application with the US Food and Drug Administration for approval of the ORPATHYS-TAGRISSO combination in pat...
Hutchmed says AstraZeneca submits NDA for ORPATHYS+TAGRISSO in NSCLC
Hutchmed (HCM) “announces that AstraZeneca (AZN) has submitted a New Drug Application to the US Food and Drug Administration for ORPATHYS (savolitinib) plus TAGRISSO(R) (osimertinib) for the treatment...
HUTCHMED Announces Submission of US NDA for ORPATHYS® plus TAGRISSO® in MET-Driven EGFR-Mutated Lung Cancer
— Filing seeks approval for a biomarker-directed, all-oral treatment option for patients whose tumors have MET overexpression or amplification, after progression on an EGFR-TKI therapy —
HUTCHMED Starts Global Phase 1 Trial Of KRAS-EGFR Therapy HMPL-A830 In Solid Tumors
(RTTNews) - HUTCHMED (China) Limited (HCM) on Monday announced the initiation of the Phase 1a portion of a global clinical trial evaluating HMPL-A830 in patients with unresectable, advanced or metasta...
Hutchmed initiates Phase Ia part of trial of HMPL-A830
Hutchmed (HCM) announces that it has initiated the Phase Ia part of a global clinical trial of HMPL-A830 in patients with unresectable, advanced or metastatic solid tumors. The first patient…
HUTCHMED Initiates Global Trial of KRAS-EGFR-Antibody Conjugate Therapy HMPL-A830 in Patients with Solid Tumors
HONG KONG and SHANGHAI and FLORHAM PARK, N.J., Sept. 27, 2026 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED” or the “Company”) (Nasdaq/AIM:HCM; HKEX:13) today announces that it has initiated...
HUTCHMED Highlights Clinical Data to be Presented at the ESMO Congress 2026
HONG KONG and SHANGHAI and FLORHAM PARK, N.J., Sept. 23, 2026 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:HCM; HKEX:13) today announces that new and updated data from sever...